A. W. Armstrong, “Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in moderate to severe plaque psoriasis: efficacy by baseline body surface area (BSA) involvement and baseline Psoriasis Area and Severity Index (PASI)”, J of Skin, vol. 7, no. 2, p. s120, Mar. 2023.